Eyepoint Pharmaceuticals (EYPT) Projected to Post Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Eyepoint Pharmaceuticals to announce earnings of ($0.9304) per share and revenue of $0.23 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. On average, analysts expect Eyepoint Pharmaceuticals to post ($3.46) EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $0.36 on Wednesday. The company has a fifty day moving average of $3.53 and a 200-day moving average of $11.25. The company has a market capitalization of $31.31 million, a PE ratio of -0.10 and a beta of 1.67. Eyepoint Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $19.11.

Analysts Set New Price Targets

EYPT has been the topic of several recent research reports. Citigroup cut their price objective on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a report on Tuesday, August 18th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, October 20th. Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday, August 17th. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Finally, Wall Street Zen raised Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $21.85.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious eye diseases. The company specializes in sustained-release drug delivery for the retina and other parts of the eye, with the goal of reducing the frequency of injections and improving treatment convenience for patients.

EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide intravitreal implant used to treat chronic noninfectious posterior uveitis, and DEXYCU, an ophthalmic formulation of dexamethasone used to treat inflammation following ocular surgery.